The Next Pandemic Won't Start in a Wet Market

Public discussion of pandemics is still heavily influenced by historical outbreaks such as SARS, avian influenza, Ebola, and COVID-19. These events reinforced a mental model in which biological threats emerge primarily from interactions between humans and animals.

This model remains important because zoonotic spillover continues to represent a major source of infectious disease emergence. However, preparedness strategies that focus exclusively on spillover risk risk overlooking how biotechnology is changing the broader threat landscape.

The challenge is not that the traditional model is wrong. The challenge is that it is increasingly incomplete.

Over the last two decades, biology has undergone a transformation similar to what happened in computing. Tasks that once required large institutions, expensive equipment, and highly specialized expertise have become more accessible, automated, and scalable.

DNA synthesis has become cheaper. Computational biology has become more powerful. Laboratory automation continues to improve. AI systems increasingly assist with scientific workflows and biological analysis.

These developments are overwhelmingly positive for medicine, agriculture, diagnostics, and biotechnology. However, they also increase the importance of governance, safety culture, and risk management.

Biotechnology is no longer confined to a small number of national laboratories, pharmaceutical companies, and elite research institutions. More actors can now access tools, protocols, equipment, cloud laboratories, genetic data, and biological design capabilities.

This democratization can accelerate discovery and expand access to innovation. It can also make the risk environment more complex because oversight becomes harder when capabilities are distributed across many organizations, countries, and informal networks.

The policy challenge is to preserve the benefits of a growing biotechnology ecosystem while reducing the probability that powerful tools are used carelessly or maliciously.

Many scientific advances are dual-use by nature. The same knowledge that helps researchers understand pathogens, develop vaccines, and improve surveillance can sometimes be applied in ways that increase biological risk.

This creates a governance challenge rather than a scientific one. Society benefits enormously from open scientific inquiry, yet some forms of research may require additional oversight because of their potential consequences if misused.

The question is not whether research should continue. The question is how innovation can proceed while maintaining appropriate safeguards.

Discussions about biological risk often focus on deliberate misuse. Yet history suggests that accidents deserve significant attention as well.

Complex systems occasionally fail. Human error occurs. Safety procedures break down. Laboratory incidents have happened in many countries and across multiple scientific disciplines.

As biological research becomes more widespread and technologically capable, maintaining strong safety cultures becomes increasingly important.

AI does not automatically create biological catastrophe. But it can accelerate parts of biological research, including literature review, hypothesis generation, protein design, experimental planning, and interpretation of complex biological data.

That acceleration has enormous upside for drug discovery, diagnostics, vaccine development, and basic science. The concern is that the same acceleration could eventually reduce barriers to harmful biological work if governance, monitoring, and safety norms fail to keep pace.

Biosecurity planning therefore has to consider not just biology and not just AI, but the convergence between the two.

Preparedness is not only about preventing biological events. It is also about detecting them quickly and responding effectively.

A future outbreak may emerge in a remote region, within a dense urban environment, or through pathways that do not fit historical expectations. Delayed detection can dramatically increase the scale of an event.

Surveillance, genomic monitoring, international information sharing, and rapid-response systems therefore become critical components of modern biosecurity.

Traditional preparedness often focuses on stockpiles, emergency plans, and healthcare capacity. These remain essential but are primarily response mechanisms.

An intelligence-oriented approach attempts to identify risk earlier by monitoring scientific developments, biotechnology capabilities, geopolitical dynamics, laboratory safety trends, pathogen surveillance, and emerging vulnerabilities.

The objective is not to predict specific events with certainty. The objective is to improve awareness and shorten the time between emerging risk and effective action.